Antithrombin III in healthy dogs and in dogs suffering from babesiosis

Veterinarski Arhiv

Volumn 75, Issue 6, 2005, Pages 477-486

  Mrljak, Vladimir ^a   Rafaj, Renata Barić ^a   Sušić, Velimir ^a   Matijatko, Vesna ^a   Kučer, Nada ^a   Kiš, Ivana ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Antithrombin III; Babesiosis; Dog

Indexed keywords

BABESIA; BABESIA CANIS; CANIS FAMILIARIS;

EID: 30744473747     PISSN: 03725480     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. BARIĆ RAFAJ, R., A. MARINCULIĆ, V. MRLJAK, B. RAIĆ, Z. ŽVORC, P. RAMADAN (2001): Activation du facteur Hageman chez les chiens atteints de babesiose. Revue Med. Vet. 152, 545-547.
2. BATEMAN, S. W., K. A. MATHEWS, A. C. G. ABRAMS-OGG, J. H. LUMSDEN, I. B. JOHNSTONE, T. K. HILLERS (1999): Evaluation of point-of-care test for diagnosis of disseminated intravascular coagulation in dogs admitted to an intensive care unit. JAVMA 215, 805-810.
3. BICK, R. (1988): Disseminated intravascular coagulation and related syndromes: A clinical review. Sem. Thromb. Hemost. 14, 299-338.
4. BICK, R., W. F. BAKER (1992): Disseminated intravascular coagulation. Hematol. Pathol. 6, 1-24.
5. BOUDREAUX, M. K., R. C. WEISS, N. COX, J. S. SPANO (1989): Evaluation of antithrombin-III activity as a coindicator of disseminated intravascular coagulation in cats with induced feline infectious peritonitis virus infection. Am. J. Vet. Res. 50, 1910-1913.
6. CALDIN, M., G. LUBAS, T. FURLANELLO, M. C. SPINNATO, A.J. DELGADILLO (1996): Preliminary investigations of AT III levels in dogs in relationship to the most common haemostatic profiles. Proc. VI European Society Veterinary Internal Medicine, 12-14 September 1996, pp. 80.
7. th European FECAVA/SCIVAC Congress, 18-21 June, Bologna, Italy, pp. 127-129.
8. FOURRIER, F., C. CHOPIN, J. GOUDEMAND, S. HENDRYCX, C. CARON, A. RIME, A. MAREY, P. LESTAVEL (1992): Septic shock, multiple organ failure, and disseminated intravascular coagulation: compared patterns of antithrombin III, protein C and protein S deficiencies. Chest 101, 816-823.
9. GREEN, R. A. (1984): Clinical implications of antithrombin III deficiency in animal diseases. Compendium Continuing Education 6, 537-545.
10. GREEN, R. A., A. L. KABEL (1982): Hypercoagulable state in three dogs with nephrotic syndrome: role of acquired antithrombin-III deficiency. JAVMA 181, 914-917.
11. HAIRE, W. D., E. I. RUBA, L. C. STEPHENS, E. REED, S. R. TARANTOLO, Z. S. PAVLETIC, P. J. BIERMAN, M. BISHOP, A. KESSINGER, J. VOSEOSE, J. O. ARMITAGE (1998): A prospective randomized double-blind trial of antithrombin III concentrate in the treatment of multiple-organ dysfunction syndrome during hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 4, 142-150.
12. HELGREN, M., N. EGBERG, J. EKLUND (1984): Blood coagulation and fibrinolytic factors and their inhibitors in critically ill patients. Intensive Care Med. 10, 23-28.
13. HESSELVIK, J. F., M. BLOMBACK, B. BRODIN, R. MALLER (1989): Coagulation, fibrinolysis, and kallikrein systems in sepsis. Crit. Care Med. 17, 724-733.
14. JACOBSON, L. S., G. E. SWAN (1995): Supportive treatment of canine babesiosis. J. S. Afr. Vet. Assoc. 66, 95-105.
15. JOCHUM, M. (1995): Influence of high-dose antithrombin concentrate therapy on the cellular proteinases, cytokines, and soluble adhesion molecules in acute inflammation. Semin. Hematol. 32 (suppl. 2), 19-32.
16. JOHNSTONE, I. B., K. H. MCANDREW, J. D. BAIRD (1986): Early detection and successful reversal of disseminated intravascular coagulation in a Thoroughbred mare presented with a history of diarrhoea and colic. Equine Vet. J. 18, 337-340.
17. KAINOH, M., R. IMAI, T. UMETSU, M. HATTORI, S. NISHIO (1990): Prostacyclin and beraprost sodium as suppressors of activated rat polymorphonuclear leukocytes. Biochem. Pharmacol. 39, 477-484.
18. KARGES, H. E., K. A. FUNK, H. RONNEBERGER (1994): Activity of coagulation and fibrinolysis paremeters in animals. Arzneim. Forsch./Drug. Res. 44, 793-797.
19. KIRBY, R. (2000): Disseminated intravascular coagulation. WSAVA-FECAVA World Congress, April 25-29, 2000, Amsterdam, Netherlands, pp. 131-132.
20. LOBETTI, R. G. (1998): Canine babesiosis. Compendium Continuing Education 20, 418-431.
21. MAMMEN, F. F. (1983): Inhibitor abnormalities. Sem. Thromb. Hemost. 9, 42-49.
22. MISCHKE, R. (1998): Hamostasestörungen als Komplikation der autoimmunhämolytischen Anämie beim Hund. Dtsch. Tierärztl. Wschr. 105, 13-16.
23. OLDS, R. J., D. A. LANE, B. MILLE, V. CHOWDHURY, S. L. THEIN (1994): Antithrombin: The principle inhibitor of thrombin. Sem. Thromb. Hemost. 20, 353-372.
24. OWINGS, J. T., M. BAGLEY, R. GOSSELIN, D. ROMAC, E. DISBROW (1996): Effect of critical injury on plasma antithrombin activity: low antithrombin levels are associated with thromboembolic complications. J. Trauma. 41, 396-405.
25. PEREIRA, P. C. M., R. C. BURINI (1992): Reacao metabolica a infeccao no hospedeiro. Rev. Hosp. Clin. Fac. Med. Sao Paulo, 47, 111-116.
26. REDENS, T. B., T. E. EMERSON (1989): Antithrombin-III treatment limits disseminated intravascular coagulation in endotoxemia. Circ. Shock 28, 49-58.
27. SHAW, S. E., M. J. DAY, R. J. BIRTLES, E. B. BREITSCHWERDT (2001): Tick-borne infectious diseases of dogs. Trends Parasitol. 17, 74-80.
28. SLAPPENDEL, R. J. (1988): Disseminated intravascular coagulation. Vet. Clin. North. Am. Small Anim. Pract. 18, 169-184.
29. SOFTIĆ, N. (1984): Hematološke laboratorijske pretrage. Sveučilišna naklada Liber, Zagreb, pp. 57.
30. UCHIBA, M., K. OKAJIMA, K. MURAKAMI, H. OKABE, K. TAKATSUKI (1995): Effects of antithrombin III (AT III) and TRP 49-modified AT III on plasma level of 6-keto-PGF 1α in rats. Thromb. Res. 80, 201-208.
31. VAN LEEUWEN, M. A., M. H. VAN RIJSWIJK (1994): Acute phase proteins in the monitoring of inflammatory disorders. Baillieres Clin. Reumatol. 8, 531-552.
32. VINAZZER, H. (1987): Clinical use antithrombin III concentrates. Vox. Sang 53, 193-198.
33. WELZL, C., A. L. LEISEWITZ, L. S. JACOBSON, T. VAUGHAN-SCOTT, E. MYBURGH (2001): Systemic inflammatory response syndrome and multiple-organ damage/dysfunction in complicated canine babesiosis. J. S. Afr. vet. Ass. 72, 1-5.
34. ed, Baltimore, Willians&Wilkins, pp. 1569-1588.